SCHEMBL1866486

SCHEMBL1866486

CCOC(=O)C1=CC2(CC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl)O[C@H](CO)[C@@H](CO)O2

nearest known ligand 0.65

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 9/20 0.65
MRGPRX1 Q96LB2 4/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 1/20 0.36
TSPO P30536 1/20 0.35
HRH1 P35367 1/20 0.35
TP53 P04637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1862533 1.00 TLR4 (0.65) TLR4MRGPRX1LMNAKMT2ATSPO
SCHEMBL1866346 1.00 TLR4 (0.65) TLR4MRGPRX1LMNAKMT2ATSPO
SCHEMBL1862850 1.00 TLR4 (0.65) TLR4MRGPRX1LMNAKMT2ATSPO
SCHEMBL1863029 0.92 TLR4 (0.63) TLR4MRGPRX1LMNAKMT2ATSPO
SCHEMBL1864585 0.92 TLR4 (0.63) TLR4MRGPRX1LMNAKMT2ATSPO
SCHEMBL1863515 0.92 TLR4 (0.53) TLR4MRGPRX1TSPOHRH1TP53
SCHEMBL1869229 0.92 TLR4 (0.53) TLR4MRGPRX1LMNAKMT2AHRH1
SCHEMBL12634813 0.92 TLR4 (0.53) TLR4MRGPRX1LMNATSPOHRH1
SCHEMBL1869580 0.92 TLR4 (0.53) TLR4MRGPRX1LMNAKMT2A
SCHEMBL1865197 0.92 TLR4 (0.53) TLR4MRGPRX1TSPOHRH1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2620434-B1 A METHOD OF PREPARING CRYSTALS OF A SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-01-04 EP claimed
US-8933117-B2 Crystals of substituted cycloalkene derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-13 US claimed
US-20140073689-A9 Crystals of Substituted Cycloalkene Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US claimed
EP-2620434-A1 CRYSTALS OF SUBSTITUTED CYCLOALKENE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-31 EP claimed
US-20130178521-A1 Crystals of Substituted Cycloalkene Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-11 US claimed
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US claimed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US claimed
EP-2620434-B1 A METHOD OF PREPARING CRYSTALS OF A SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-01-04 EP disclosed
EP-2620434-B1 A METHOD OF PREPARING CRYSTALS OF A SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2017-01-04 EP disclosed
US-8933117-B2 Crystals of substituted cycloalkene derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-13 US disclosed
US-8933117-B2 Crystals of substituted cycloalkene derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-13 US disclosed
US-20140073689-A9 Crystals of Substituted Cycloalkene Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
EP-2620434-A1 CRYSTALS OF SUBSTITUTED CYCLOALKENE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-31 EP disclosed
EP-2620434-A1 CRYSTALS OF SUBSTITUTED CYCLOALKENE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-31 EP disclosed
EP-2620434-A1 CRYSTALS OF SUBSTITUTED CYCLOALKENE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-31 EP disclosed
US-20130178521-A1 Crystals of Substituted Cycloalkene Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-11 US disclosed
WO-2012039447-A1 CRYSTALS OF SUBSTITUTED CYCLOALKENE DERIVATIVES 第一三共株式会社 (JP) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178521-A1 Crystals of Substituted Cycloalkene Derivatives BAD, PYCARD, CASP8 TLR4 8/4885MRGPRX1 899/4885LMNA 3724/4885
US-20140073689-A9 Crystals of Substituted Cycloalkene Derivatives BAD, PYCARD, CASP8 TLR4 8/4885MRGPRX1 899/4885LMNA 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.